elranatamab
pfizer
['mmsm', 'multiple myeloma', 'elranatamab', '2110']
. presents results with the use of elrantamab in relapsed/refractory myeloma, with reductions in soluble bcma in patients who achieved vgpr and cr with an overall response of 64% and progression-free survival rates of 12 months. #ash22 #mmsm 
Supporting, educating and connecting myeloma patients and their loved ones while actively seeking a cure. #myeloma #mmsm #hematology #multiplemyeloma